Central nervous system adverse effects of new antiepileptic drugs

Zaccara, Gaetano; Gangemi, Pierfranco; Cincotta, Massimo

doi:10.1016/j.seizure.2007.12.003

Cited by 103 publications

(51 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OXC may cause hyponatremia more often than CBZ. Levetiracetam (LEV), which has a better tolerability profile (34), share many of the advantages offered by LTG and GBP, although these drugs have not yet been assessed in this population of patients.…”

Section: Treatment Recommendationsmentioning

confidence: 99%

Neurological comorbidity and epilepsy: implications for treatment

Zaccara¹

2009

Acta Neurologica Scandinavica

Self Cite

View full text Add to dashboard Cite

Section: Treatment Recommendationsmentioning

confidence: 99%

Neurological comorbidity and epilepsy: implications for treatment

Zaccara¹

2009

Acta Neurologica Scandinavica

Self Cite

View full text Add to dashboard Cite

“…[21][22][23] A meta-analysis by Zaccara and colleagues compared the central nervous system effects of various new antiepileptic drugs from randomized double-blind trials and found that levetiracetam was significantly associated with somnolence. 66 Although this meta-analysis did not find a relationship between somnolence and drug dose, other clinical trials have seen a dose response relationship. 21 Bootsma and colleagues have reported that somnolence or tiredness appeared to be more common in patients without mental handicap compared to those with mental handicaps.…”

Section: Safety Tolerability and Adverse Effectsmentioning

confidence: 60%

Pharmacotherapy of Epilepsy: Focus on Levetiracetam

Adams

Chung

Eiland

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Abstract:Levetiracetam is a second-generation antiepileptic drug which first came to the United States market in 1999. It has a mechanism of action that is not well elucidated. However, it is a very favorable antiepileptic drug due to its reliable pharmacokinetics, minimal drug interactions, seizure efficacy and good tolerability. It is an agent that has established efficacy as an adjunct therapy agent for partial and refractory seizures. As a monotherapy agent, levetiracetam also appears to be an attractive agent with observed efficacy and tolerability. Since levetiracetam has recently become available intravenously, it is also being reviewed as an agent for acute status epilepticus. In pediatrics, levetiracetam is widely used with efficacy seen in small clinical trials for a variety of seizure types. Levetiracetam is well tolerated: the most common adverse effect being somnolence and behavioral effects. Overall, levetiracetam is a notable antiepileptic drug that has added significantly to the current antiepileptic armamentarium.

show abstract

“…This is typically done proactively rather than in response to a specific problem. For example, many AEDs contribute to dizziness, sedation, fatigue, and inattention [16]. Additionally, some of the older AEDs (such as phenytoin and valproate) affect hepatic enzyme metabolism which is particularly undesirable for patients taking multiple medications.…”

Section: Discussionmentioning

confidence: 99%

“…After successful seizure control, AED polypharmacy may lead to adverse side effects, drug-drug interactions between AEDs and non-AEDs, and excessive cost for patients after hospital discharge if their polypharmacy regimen is continued. Common AED side effects include dizziness, fatigue, nausea and cognitive dysfunction [16]. AED weaning after successful seizure control may avoid or minimize these complications.…”

Section: Introductionmentioning

confidence: 99%